Boron-containing purines, pyrimidines, thymidines, nucleosides and nucleotides also have been investigated as BNCT delivery agents, in particular 3-carboranyl thymidine analogues (3CTAs), which specifically target thymidine kinase-1 (TK1)-expressing tumor cells [67–69]. This evidence concerns the gene TK1 and neoplasm.